The Medication(s) listed below have been approved by the Food & Drug Administration (FDA) as orphan products for treatment of this condition. There may be other products available
that are not considered orphan products.
Clofazimine (Brand name: Lamprene®)
- Manufactured by
Novartis Pharmaceutical Corporation
FDA-approved indication: Treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum.
National Library of Medicine Drug Information Portal